Home > Insider Trading > Filing (0001651308-19-000085)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1651308	Beigene Ltd.	BGNE	Pharmaceutical Preparations (2834)	981209416

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1683913	Jane Huang	C/O Mourant Governance Services (Cayman) 94 Solaris Avenue Camana Bay, Grand Cayman E9 KY1-1108	Cmo, Hematology	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
American Depositary Shares	Disposition	2019-09-03	2,632	$144.41	230	No	4	S	Direct
American Depositary Shares	Disposition	2019-09-03	230	$144.94	0	No	4	S	Direct
American Depositary Shares	Disposition	2019-09-04	82	$129.40	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares	291,667	Direct

Footnotes

Each American Depositary Share ("ADS") represents 13 Ordinary Shares.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligation in connection with the vesting of a restricted share award previously granted to the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.88 to $144.84, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.90 to $144.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
These shares were acquired under the BeiGene, Ltd. Second Amended and Restated Employee Share Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).